文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

ATM缺失对前列腺癌模型镭-223放射生物学与免疫反应的影响

Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-05-30

本研究在前列腺癌体外模型中比较X射线与镭-223(223Ra)对ATM缺失与野生型细胞的放射生物学和免疫反应。结果显示223Ra较X射线显著增加放射敏感性,ATM缺失进一步放大该效应,并诱导更多DNA损伤、G2期积聚、凋亡及cGAS/STING炎症基因上调。提示ATM缺失可作为223Ra疗效决定因素和治疗靶点。

要点

  • 223Ra较X射线显著增加前列腺癌细胞放射敏感性,ATM缺失进一步放大该效应。
  • ATM缺失细胞经223Ra处理后24h持续53BP1焦点增多、G2期积聚及凋亡增加。
  • 223Ra在ATM缺失细胞中触发cGAS阳性微核及STING驱动炎症基因上调。

核心结论

  • ATM缺失增强前列腺癌细胞对223Ra的放射生物学反应并放大免疫激活,支持将ATM缺失作为223Ra疗效决定因素和治疗靶点进一步临床前评估。

研究设计与样本

  • 研究采用CRISPR Cas介导的等基因ATM缺失与野生型前列腺癌细胞,分别接受X射线或氯化镭-223处理。
  • 通过克隆形成实验测放射敏感性,53BP1免疫荧光评估DNA损伤,流式细胞术分析细胞周期与凋亡。
  • 采用cGAS免疫荧光及CCL5、CXCL10、IFIT2定量PCR评估先天免疫激活。

主要发现

  • 223Ra较X射线显著增加放射敏感性,且该效应在ATM缺失时被放大。
  • ATM缺失的PC-3和DU145细胞经223Ra处理后24h持续53BP1焦点显著增多、G2期积聚及凋亡升高,均优于X射线或野生型对照(p < 0.05)。
  • 223Ra在ATM缺失细胞中触发cGAS阳性微核及STING驱动炎症基因上调(p < 0.05)。

关键数值与推荐

  • ATM缺失细胞经223Ra处理后24h持续53BP1焦点、G2期积聚和凋亡较X射线或野生型对照显著增加(p < 0.05)。
  • 223Ra在ATM缺失细胞中诱导cGAS阳性微核及STING驱动炎症基因上调(p < 0.05)。

临床怎么用

  • 对于mCRPC患者,ATM缺失状态可能提示223Ra治疗应答更优,支持开展临床前/转化研究验证其作为疗效决定因素。
  • 223Ra联合STING/先天免疫通路激活可能成为ATM缺失前列腺癌的潜在策略,但需进一步体内和临床研究。

局限性

  • 研究仅为体外细胞模型,未涉及体内微环境、临床样本或患者结局。
  • 原文未报告ATM缺失对223Ra疗效的临床阈值或剂量-效应关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Personalised medicine approaches are redefining the therapeutic landscape for men with metastatic castration-resistant prostate cancer (mCRPC). While poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit in patients with BRCA1/2 mutant tumours, the therapeutic efficacy of these inhibitors in Ataxia-telangiectasia mutated (ATM)-mutated prostate cancer patients remains modest, highlighting the need for alternative treatment strategies. This study aimed to elucidate the impact of ATM loss on radiobiological and immune responses to different radiation modalities in prostate cancer models. METHODS: Isogenic CRISPR Cas-mediated ATM-deficient and wild-type (WT) cells were treated with X-rays or Radium-223 dichloride (223Ra). Cellular radiosensitivity was measured using clonogenic assays and 53BP1 immunofluorescence assessed DNA damage. Cell cycle distribution and apoptosis were analysed by flow cytometry. Innate immune activation was assessed using cGAS immunofluorescence and quantitative PCR of CCL5, CXCL10 and IFIT2. RESULTS: 223Ra significantly increased radiosensitivity in comparison to X-rays which was amplified by ATM loss. 223Ra exposure in ATM deficient cells induced significantly greater levels of DNA damage as measured by persistent 53BP1 foci at 24h, distinct G2 accumulation and elevated levels of apoptosis in PC-3 and DU145 ATM-deficient cells in comparison to either X-rays or WT counterparts (p < 0.05). Furthermore, 223Ra triggered cGAS positive micronuclei and upregulation of STING driven inflammatory genes, particularly in ATM-deficient cells (p < 0.05). CONCLUSIONS: These findings demonstrate that ATM-deficiency enhances radiobiological response and amplifies immune activation to 223Ra, supporting further pre-clinical evaluation of ATM loss as a determinant of response and therapeutic target to optimise 223Ra based strategies for mCRPC.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dunne VL, Wright TC, Toner A, et al. Impact of ataxia-telangiectasia mutated (ATM) loss on radiobiological and immune response to radium-223 in prostate cancer in vitro models. Clin Transl Radiat Oncol. 2026. PMID: 42291797. doi:10.1016/j.ctro.2026.101206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。